|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rucci N and Angelucci A: Prostate cancer
and bone: The elective affinities. Biomed Res Int. 2014:1670352014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saad F, Lipton A, Cook R, Chen YM, Smith M
and Coleman R: Pathologic fractures correlate with reduced survival
in patients with malignant bone disease. Cancer. 110:1860–1867.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zustovich F and Fabiani F: Therapeutic
opportunities for castration-resistant prostate cancer patients
with bone metastases. Crit Rev Oncol Hematol. 91:197–209. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Albagli O, Dhordain P, Deweindt C, Lecocq
G and Leprince D: The BTB/POZ domain: A new protein-protein
interaction motif common to DNA- and actin-binding proteins. Cell
Growth Differ. 6:1193–1198. 1995.PubMed/NCBI
|
|
7
|
Stogios PJ, Downs GS, Jauhal JJ, Nandra SK
and Privé GG: Sequence and structural analysis of BTB domain
proteins. Genome Biol. 6:R822005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bardwell VJ and Treisman R: The POZ
domain: A conserved protein-protein interaction motif. Genes Dev.
8:1664–1677. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Rao S, Chu J, Shen X, Levasseur
DN, Theunissen TW and Orkin SH: A protein interaction network for
pluripotency of embryonic stem cells. Nature. 444:364–368. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim J, Chu J, Shen X, Wang J and Orkin SH:
An extended transcriptional network for pluripotency of embryonic
stem cells. Cell. 132:1049–1061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakayama K, Nakayama N, Davidson B, Sheu
JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman
RJ, et al: A BTB/POZ protein, NAC-1, is related to tumor recurrence
and is essential for tumor growth and survival. Proc Natl Acad Sci
USA. 103:pp. 18739–18744. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jinawath N, Vasoontara C, Yap KL,
Thiaville MM, Nakayama K, Wang TL and Shih IM: NAC-1, a potential
stem cell pluripotency factor, contributes to paclitaxel resistance
in ovarian cancer through inactivating Gadd45 pathway. Oncogene.
28:1941–1948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Cheng Y, Ren X, Hori T,
Huber-Keener KJ, Zhang L, Yap KL, Liu D, Shantz L, Qin ZH, et al:
Dysfunction of nucleus accumbens-1 activates cellular senescence
and inhibits tumor cell proliferation and oncogenesis. Cancer Res.
72:4262–4275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL,
Wu H, Patel R, Liu D, Qin ZH, Shih IM and Yang JM: NAC1 modulates
sensitivity of ovarian cancer cells to cisplatin by altering the
HMGB1-mediated autophagic response. Oncogene. 31:1055–1064. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yap KL, Fraley SI, Thiaville MM, Jinawath
N, Nakayama K, Wang J, Wang TL, Wirtz D and Shih IeM: NAC1 is an
actin-binding protein that is essential for effective cytokinesis
in cancer cells. Cancer Res. 72:4085–4096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao M, Wu RC, Herlinger AL, Yap K, Kim JW,
Wang TL and Shih IeM: Identification of the NAC1-regulated genes in
ovarian cancer. Am J Pathol. 184:133–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yeasmin S, Nakayama K, Ishibashi M,
Katagiri A, Iida K, Purwana IN, Nakayama N and Miyazaki K:
Expression of the bric-a-brac tramtrack broad complex protein NAC-1
in cervical carcinomas seems to correlate with poorer prognosis.
Clin Cancer Res. 14:1686–1691. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takayanagi H, Kim S, Matsuo K, Suzuki H,
Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al: RANKL
maintains bone homeostasis through c-Fos-dependent induction of
interferon-beta. Nature. 416:744–749. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishikawa M, Nakayama K, Yeasmin S,
Katagiri A, Iida K, Nakayama N and Miyazaki K: NAC1, a potential
stem cell pluripotency factor expression in normal endometrium,
endometrial hyperplasia and endometrial carcinoma. Int J Oncol.
36:1097–1103. 2010.PubMed/NCBI
|
|
20
|
Rahman MT, Nakayama K, Ishikawa M, Rahman
M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Yamada T and
Miyazaki K: NAC1, a BTB/POZ protein overexpressed in uterine
sarcomas. Anticancer Res. 32:3841–3845. 2012.PubMed/NCBI
|
|
21
|
Zhang Y, Yang JW, Ren X and Yang JM: NAC1
and HMGB1 enter a partnership for manipulating autophagy.
Autophagy. 7:1557–1558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ju T, Jin H, Ying R, Xie Q, Zhou C and Gao
D: Overexpression of NAC1 confers drug resistance via HOXA9 in
colorectal carcinoma cells. Mol Med Rep. 16:3194–3200. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Faiola F, Yin N, Fidalgo M, Huang X,
Saunders A, Ding J, Guallar D, Dang B and Wang J: NAC1 regulates
somatic cell reprogramming by controlling Zeb1 and E-cadherin
expression. Stem Cell Rep. 9:913–926. 2017. View Article : Google Scholar
|
|
24
|
Hayashida C, Ito J, Nakayachi M, Okayasu
M, Ohyama Y, Hakeda Y and Sato T: Osteocytes produce interferon-β
as a negative regulator of osteoclastogenesis. J Biol Chem.
289:11545–11555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grigoriadis AE, Wang ZQ, Cecchini MG,
Hofstetter W, Felix R, Fleisch HA and Wagner EF: c-Fos: A key
regulator of osteoclast-macrophage lineage determination and bone
remodeling. Science. 266:443–448. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kieran MW, Kalluri R and Cho YJ: The VEGF
pathway in cancer and disease: Responses, resistance, and the path
forward. Cold Spring Harb Perspect Med. 2:a0065932012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Potente M, Gerhardt H and Carmeliet P:
Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Panneerselvam J, Jin J, Shanker M,
Lauderdale J, Bates J, Wang Q, Zhao YD, Archibald SJ, Hubin TJ and
Ramesh R: IL-24 inhibits lung cancer cell migration and invasion by
disrupting the SDF-1/CXCR4 signaling axis. PLoS One.
10:e01224392015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Song W, Shen W, Yang X, Sun W, Qu
S, Shang R, Ma B, Pu M, Tao K, et al: MicroRNA-200a suppresses cell
invasion and migration by directly targeting GAB1 in hepatocellular
carcinoma. Oncol Res. 25:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lim SY, Yuzhalin AE, Gordon-Weeks AN and
Muschel RJ: Tumor-infiltrating monocytes/macrophages promote tumor
invasion and migration by upregulating S100A8 and S100A9 expression
in cancer cells. Oncogene. 35:5735–5745. 2016. View Article : Google Scholar : PubMed/NCBI
|
